This is relevant as effector cell expansion positively relates to therapy outcome in both CAR-T cell and bsTCE therapy in patients.47,48 Expression of CD1d on tumor cells was confirmed in the majority of MM, (myelo)monocytic AML, and CLL patients, and the CD1d-Vδ2 bsTCE-mediated ...